Atea Pharmaceuticals (AVIR) News Today $3.19 +0.03 (+0.95%) Closing price 04:00 PM EasternExtended Trading$3.12 -0.06 (-2.04%) As of 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVIR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Two Sigma Advisers LP Sells 88,800 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)Two Sigma Advisers LP trimmed its position in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 15.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 493,600 shares of the company's stock after selliMay 31, 2025 | marketbeat.comBNP Paribas Financial Markets Buys New Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)BNP Paribas Financial Markets purchased a new position in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 96,433 shares of the company's stoMay 28, 2025 | marketbeat.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Holdings Increased by Tang Capital Management LLCTang Capital Management LLC grew its stake in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 3.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,788,912 shares of the company's stocMay 20, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Lowers Stock Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)Jacobs Levy Equity Management Inc. decreased its position in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 23.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 390,899 shares of tMay 19, 2025 | marketbeat.comNewtyn Management LLC Purchases 200,000 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)Newtyn Management LLC boosted its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 52.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 580,000 shares of the company's stock after buying an additional 200,000 shareMay 16, 2025 | marketbeat.comDimensional Fund Advisors LP Has $3.27 Million Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)Dimensional Fund Advisors LP increased its holdings in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 23.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 977,470 shares of the company's stockMay 16, 2025 | marketbeat.comAtea Pharmaceuticals (NASDAQ:AVIR) Issues Earnings Results, Beats Expectations By $0.01 EPSAtea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) released its earnings results on Monday. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.01.May 14, 2025 | marketbeat.comAtea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comAtea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on MondayAtea Pharmaceuticals (NASDAQ:AVIR) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-atea-pharmaceuticals-inc-stock/)May 7, 2025 | marketbeat.comAtea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025May 7, 2025 | globenewswire.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Stake Lessened by Almitas Capital LLCAlmitas Capital LLC trimmed its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 45.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 752,003 shares of the company's stock after selling 632,526 shMay 4, 2025 | marketbeat.comAtea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025May 1, 2025 | globenewswire.comJPMorgan Chase & Co. Buys 314,015 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)JPMorgan Chase & Co. increased its position in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 329.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 409,259 shares of the company's stoApril 28, 2025 | marketbeat.comRBF Capital LLC Has $183,000 Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)RBF Capital LLC cut its stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 63.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 54,929 shares of the company's stock after selling 93,522 shares durApril 26, 2025 | marketbeat.comAtea Pharmaceuticals announces results from phase 2 study of bemnifosbuvirApril 24, 2025 | markets.businessinsider.comAtea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025April 23, 2025 | globenewswire.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Vanguard Group Inc.Vanguard Group Inc. decreased its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 3.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,666,854 shares of the company's stock afteApril 20, 2025 | marketbeat.comAtea Pharmaceuticals says strategic alternatives process ‘ongoing’April 17, 2025 | markets.businessinsider.comAtea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase ProgramApril 17, 2025 | globenewswire.comMorgan Stanley Remains a Hold on Atea Pharmaceuticals (AVIR)April 13, 2025 | markets.businessinsider.comMorgan Stanley Has Lowered Expectations for Atea Pharmaceuticals (NASDAQ:AVIR) Stock PriceMorgan Stanley lowered their target price on Atea Pharmaceuticals from $6.20 to $6.00 and set an "equal weight" rating on the stock in a research note on Friday.April 13, 2025 | marketbeat.comAtea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 studyApril 9, 2025 | msn.comADAR1 Capital Management LLC Invests $368,000 in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)ADAR1 Capital Management LLC bought a new stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 110,000 shares of the company'sApril 9, 2025 | marketbeat.comAtea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C VirusApril 9, 2025 | globenewswire.comDriver Notifies Atea Pharmaceuticals of Withdrawal of Notice of NominationMarch 31, 2025 | globenewswire.comAtea Pharmaceuticals, Inc.: Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder ValueMarch 30, 2025 | finanznachrichten.deAtea Pharmaceuticals takes steps to boost shareholder valueMarch 28, 2025 | investing.comAtea Pharmaceuticals cuts workforce by ~25% in Q1March 27, 2025 | msn.comAtea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder ValueMarch 26, 2025 | globenewswire.comThe Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of DirectorsMarch 26, 2025 | finance.yahoo.comAtea Pharmaceuticals, Inc.: Atea Pharmaceuticals Issues Statement Regarding Director NominationsMarch 22, 2025 | finanznachrichten.deAtea Pharmaceuticals Issues Statement Regarding Director NominationsMarch 21, 2025 | globenewswire.comAtea Pharmaceuticals, Inc. (AVIR): A Bull Case TheoryMarch 21, 2025 | insidermonkey.comAtea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025March 19, 2025 | globenewswire.comWhat is William Blair's Forecast for AVIR Q1 Earnings?Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) - Analysts at William Blair issued their Q1 2026 earnings estimates for shares of Atea Pharmaceuticals in a report issued on Friday, March 7th. William Blair analyst A. Hsieh expects that the company will post earnings per share of ($0.40) foMarch 10, 2025 | marketbeat.comAtea Pharmaceuticals Reports Successful FDA Meeting and Plans Phase 3 Program for Hepatitis C TreatmentMarch 8, 2025 | nasdaq.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2024 Earnings Call TranscriptMarch 8, 2025 | msn.comAtea Pharmaceuticals (NASDAQ:AVIR) Receives "Outperform" Rating from William BlairWilliam Blair reissued an "outperform" rating on shares of Atea Pharmaceuticals in a research report on Friday.March 8, 2025 | marketbeat.comBML Capital Management LLC Has $25.49 Million Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)BML Capital Management LLC lifted its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 14.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,608,312 shares of the company's sMarch 8, 2025 | marketbeat.comAtea Pharmaceuticals Faces Challenges Amid Workforce Reductions and Cost-Cutting EffortsMarch 8, 2025 | tipranks.comAtea Pharmaceuticals’ Promising Earnings Call HighlightsMarch 7, 2025 | tipranks.comAtea Pharmaceuticals (NASDAQ:AVIR) Posts Quarterly Earnings ResultsAtea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.05).March 7, 2025 | marketbeat.comAtea Pharmaceuticals reports Q4 EPS (40c), consensus (29c)March 6, 2025 | markets.businessinsider.comAtea Pharmaceuticals, Inc. (AVIR) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | seekingalpha.comAtea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 6, 2025 | globenewswire.comAtea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on ThursdayAtea Pharmaceuticals (NASDAQ:AVIR) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.March 1, 2025 | marketbeat.comAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025February 27, 2025 | globenewswire.comAtea Pharmaceuticals, Inc.: Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of DirectorsFebruary 24, 2025 | finanznachrichten.deAtea Pharmaceuticals Appoints Arthur S. Kirsch to Board of DirectorsFebruary 24, 2025 | globenewswire.comAtea Pharmaceuticals (AVIR) Expected to Announce Earnings on WednesdayAtea Pharmaceuticals (NASDAQ:AVIR) will be releasing earnings before the market opens on Wednesday, February 26.February 19, 2025 | marketbeat.com Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address AVIR Media Mentions By Week AVIR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVIR News Sentiment▼1.890.90▲Average Medical News Sentiment AVIR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVIR Articles This Week▼12▲AVIR Articles Average Week Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Wave Life Sciences News Niagen Bioscience News Mineralys Therapeutics News Arcus Biosciences News Spyre Therapeutics News Akebia Therapeutics News CureVac News Enliven Therapeutics News Phibro Animal Health News Collegium Pharmaceutical News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVIR) was last updated on 6/16/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSomething Big Is Coming...Man who predicted Lehman Crash Warns "Get OUT of Cash" He predicted the 2008 crisis and recommended shortin...Stansberry Research | SponsoredBREAKING: Trump vs. Elon Feud Threatens Your Retirement – Protect Yourself NOW"This isn't just a war of words. This is a financial time bomb. The escalating battle between Donald Trump a...American Alternative | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. Chinese AI chatbot DeepSeek turned the tech world on its hea...Weiss Ratings | SponsoredWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
